The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.43
Bid: 3.06
Ask: 3.80
Change: -0.17 (-4.72%)
Spread: 0.74 (24.183%)
Open: 3.60
High: 0.00
Low: 0.00
Prev. Close: 3.60
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

14 Dec 2015 16:02

RNS Number : 0056J
Proteome Sciences PLC
14 December 2015
 

 

 

PRESS RELEASE

 

14 December 2015

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Director Dealing

 

Further to the announcement made earlier today regarding the purchase of Ordinary Shares in the Company by Vulpes Life Sciences Fund ("Vulpes"), the Company would like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 36,548,125 Ordinary Shares of the Company representing 16.03% of the issued share capital of the Company.

 

 

For further information please contact:

 

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Ian Pike, Chief Operating Officer

Tel: +44 (0)1932 865065

Geoff Ellis, Finance Director

finnCap Limited (Nominated adviser & broker)

Geoff Nash/James Thompson

Tel: +44 (0)20 7220 0500

 

Public Relations

IKON Associates

Adrian Shaw

Email: Adrian@ikonassociates.com

Tel: +44 (0)1483 271291

Mob: +44 (0)797 9900733

Tel: +44 (0)1483 271291

Mob: +44 (0)7979 900733

 

 

 

Notes to Editors:

 

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

 

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

 

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFFAFILFISEIE
Date   Source Headline
3rd Mar 20207:00 amRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSFurther Year End Trading Update, Milestone Payment
21st Jan 20207:00 amRNSYear End Trading Update
31st Oct 20197:00 amRNSTrading Update and Announcement of Board Changes
25th Jul 20197:00 amRNSInterim Results
1st Jul 20197:00 amRNSLaunch of new services powered by TMTpro 16plex
30th Apr 20193:44 pmRNSResult of AGM
30th Apr 20192:30 pmRNSAGM Statement and Q1 Trading Update
2nd Apr 20197:00 amRNSResults and Notice of AGM
14th Mar 20197:00 amRNSNotice of Results
23rd Jan 20197:00 amRNSYear End Trading Update
20th Dec 20187:00 amRNSAppointment of Nominated Adviser and Broker
10th Dec 20189:26 amRNSHolding(s) in Company
26th Nov 20184:38 pmRNSDirector/PDMR Shareholding
23rd Nov 20181:26 pmRNSDirector/PDMR Shareholding
21st Nov 20189:41 amRNSDirector/PDMR Shareholding
16th Nov 20182:35 pmRNSDirector/PDMR Shareholding
14th Nov 201812:10 pmRNSDirector/PDMR Shareholding
9th Nov 20184:34 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSTrading Update
12th Oct 20184:43 pmRNSDirector/PDMR Shareholding
9th Oct 20183:28 pmRNSDirector/PDMR Shareholding
8th Oct 201810:31 amRNSBlock listing Interim Review
4th Oct 20181:42 pmRNSDirector/PDMR Shareholding
1st Oct 20183:39 pmRNSDirector/PDMR Shareholding
21st Sep 20185:10 pmRNSDirector/PDMR Shareholding
12th Sep 20184:18 pmRNSDirector/PDMR Shareholding
7th Sep 20183:43 pmRNSDirector/PDMR Shareholding
14th Aug 201810:04 amRNSHolding(s) in Company
14th Aug 201810:03 amRNSDirector/PDMR Shareholding
9th Aug 20181:23 pmRNSDirector/PDMR Shareholding
2nd Aug 201810:03 amRNSDirector/PDMR Shareholding
31st Jul 20184:09 pmRNSDirector/PDMR Shareholding
27th Jul 201812:21 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSInterim Results
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20187:00 amRNSLoan Agreement and Notice of Results
18th Jun 20184:40 pmRNSSecond Price Monitoring Extn
18th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20181:36 pmRNSAGM Statement
24th Apr 20187:00 amRNSBoard Appointment
24th Apr 20187:00 amRNSPreliminary Results
3rd Apr 201810:40 amRNSBlock Admission return
3rd Apr 20187:00 amRNSLicense Agreement Extension
28th Mar 20187:00 amRNSNotice of Results
22nd Mar 20181:18 pmRNSDirector/PDMR Shareholding
15th Mar 20184:40 pmRNSSecond Price Monitoring Extn
15th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Feb 20187:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.